Physician profile
Fruma L Wiederman
NPI 1881828549
$3,423.53
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $844 · 2022: $1,362 · 2023: $990 · 2024: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.65 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,200.82 | 2021-2023 | Tremfya, Stelara, Remicade |
| Dermavant Sciences, INC. | $418.29 | 2023-2024 | Vtama |
| Amgen INC. | $253.97 | 2021-2023 | Otezla |
| Pfizer INC. | $221.78 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $207.96 | 2022 | |
| Lilly USA, LLC | $207.86 | 2021-2022 | |
| Abbvie INC. | $181.56 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $175.77 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $150.63 | 2021-2022 | |
| Almirall LLC | $146.81 | 2023 | Klisyri |
| Galderma Laboratories, L.P. | $129.65 | 2021 | |
| Genzyme Corporation | $37.88 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $30.74 | 2022-2023 | Sotyktu |
| Leo Pharma INC. | $21.37 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.10 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $17.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fruma Wiederman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.